ID   Lu-130
AC   CVCL_6862
SY   NCC-c-Lu-130; LU-130; Lu130
DR   EFO; EFO_0003142
DR   BioSample; SAMN03151826
DR   cancercelllines; CVCL_6862
DR   CGH-DB; 89-1
DR   CGH-DB; 9058-4
DR   Cosmic; 809118
DR   Cosmic; 844807
DR   Cosmic; 918004
DR   Cosmic; 1212192
DR   Cosmic; 1571748
DR   Cosmic; 2668337
DR   GEO; GSM17309
DR   IARC_TP53; 1013
DR   RCB; RCB0465
DR   Wikidata; Q54903190
RX   PubMed=1312700;
RX   PubMed=3022030;
RX   PubMed=10536175;
RX   PubMed=12107105;
RX   PubMed=15016488;
RX   PubMed=16643607;
RX   PubMed=20143388;
CC   Problematic cell line: Contaminated. Shown to be a Lu-134-A (or Lu-134-B) derivative (PubMed=16643607; PubMed=20143388). Originally thought to originate from a 61 year old male patient with small cell lung carcinoma.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00232.
CC   Population: Japanese.
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro278Leu (c.833C>T); ClinVar=VCV000232497; Zygosity=Unspecified (PubMed=1312700; PubMed=10536175).
CC   Omics: Transcriptome analysis by microarray.
CC   Discontinued: RCB; RCB0465; true.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C4917; Lung small cell carcinoma
DI   ORDO; Orphanet_70573; Small cell lung cancer
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1387 ! Lu-134-A
SX   Male
AG   80Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 26
RX   PubMed=1312700;
RA   Sameshima Y., Matsuno Y., Hirohashi S., Shimosato Y., Mizoguchi H.,
RA   Sugimura T., Terada M., Yokota J.;
RT   "Alterations of the p53 gene are common and critical events for the
RT   maintenance of malignant phenotypes in small-cell lung carcinoma.";
RL   Oncogene 7:451-457(1992).
RX   PubMed=3022030; DOI=10.1093/oxfordjournals.jjco.a039144;
RA   Terasaki T., Shimosato Y., Nakajima T., Tsumuraya M., Morinaga S.,
RA   Hirohashi S., Yamaguchi K., Kato K., Ichinose H., Nagatsu T.;
RT   "Changes in cell characteristics due to culture conditions in cell
RT   lines from human small cell lung cancer.";
RL   Jpn. J. Clin. Oncol. 16:203-212(1986).
RX   PubMed=10536175; DOI=10.3892/ijo.15.5.927;
RA   Fujita T., Kiyama M., Tomizawa Y., Kohno T., Yokota J.;
RT   "Comprehensive analysis of p53 gene mutation characteristics in lung
RT   carcinoma with special reference to histological subtypes.";
RL   Int. J. Oncol. 15:927-934(1999).
RX   PubMed=12107105; DOI=10.1016/S0002-9440(10)64172-7;
RA   Yokoi S., Yasui K., Saito-Ohara F., Koshikawa K., Iizasa T.,
RA   Fujisawa T., Terasaki T., Horii A., Takahashi T., Hirohashi S.,
RA   Inazawa J.;
RT   "A novel target gene, SKP2, within the 5p13 amplicon that is
RT   frequently detected in small cell lung cancers.";
RL   Am. J. Pathol. 161:207-216(2002).
RX   PubMed=15016488; DOI=10.1016/S0140-6736(04)15693-6;
RA   Jones M.H., Virtanen C., Honjoh D., Miyoshi T., Satoh Y., Okumura S.,
RA   Nakagawa K., Nomura H., Ishikawa Y.;
RT   "Two prognostically significant subtypes of high-grade lung
RT   neuroendocrine tumours independent of small-cell and large-cell
RT   neuroendocrine carcinomas identified by gene expression profiles.";
RL   Lancet 363:775-781(2004).
RX   PubMed=16643607; DOI=10.1111/j.1749-0774.2005.00007.x;
RA   Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T.,
RA   Obata Y., Nakamura Y.;
RT   "Essential role for gene profiling analysis in the authentication of
RT   human cell lines.";
RL   Hum. Cell 19:43-48(2006).
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).